Catalog No.: PC-23570Not For Human Use, Lab Use Only.
TD52 is a small molecule inhibitor of cancerous inhibitor of protein phosphatase 2A (CIP2A), downregulates CIP2A and p-Akt, reactivates protein phosphatase 2A.
TD52 is a small molecule inhibitor of cancerous inhibitor of protein phosphatase 2A (CIP2A), downregulates CIP2A and p-Akt, reactivates protein phosphatase 2A. TD52 causes greater reduction in cell viability than erlotinib in all the HCC cell lines tested including HA22T (IC50=0.9 μmol/l), Hep3B (IC50=0.9 μmol/l), PLC5 (IC50=0.8 μmol/l) and Sk-Hep1 (IC50=1.2 μmol/l), which is independent of EGFR kinase inhibition. TD52 downregulates the protein expression of CIP2A and p-Akt in a dose- and time-dependent manner, with no effect on the expression level of PP2A-related subunits, PP2A-A, PP2A-B55 and PP2A-C. TD52 downregulates transcription of CIP2A via interfering Elk-1 function. TD52 (10 mg/kg/day) exhibits in vivo antitumor effects on a PLC5 xenograft tumor model.
Physicochemical Properties
M.Wt
360.42
Formula
C24H16N4
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
N2,N3-Bis(3-ethynylphenyl)quinoxaline-2,3-diamine
References
1. Yu HC, et al. Cell Death Dis. 2014 Jul 31;5(7):e1359.
